AIKI
Income statement / Annual
Last year (2022), AIkido Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, AIkido Pharma Inc.'s net income was -$29.87 M.
See AIkido Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$9,000.00 |
$28,000.00 |
$1.24 M |
$877,000.00 |
$33,000.00 |
$10,000.00 |
$27,000.00 |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$81,000.00
|
$92,000.00
|
$84,000.00
|
$88,000.00
|
$864,000.00
|
$3,000.00
|
Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$9,000.00
|
-$53,000.00
|
$1.14 M
|
$793,000.00
|
-$55,000.00
|
-$854,000.00
|
$24,000.00
|
Gross Profit Ratio |
0
|
0
|
0
|
1
|
-1.89
|
0.93
|
0.9
|
-1.67
|
-85.4
|
0.89
|
Research and Development Expenses |
$830,000.00
|
$559,000.00
|
$2.49 M
|
$2.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10,000.00
|
General & Administrative Expenses |
$11.68 M
|
$7.73 M
|
$4.06 M
|
$0.00
|
$3.06 M
|
$3.69 M
|
$4.58 M
|
$5.13 M
|
$20.79 M
|
$15.07 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$11.68 M
|
$7.73 M
|
$4.06 M
|
$3.17 M
|
$3.06 M
|
$3.69 M
|
$4.58 M
|
$5.13 M
|
$20.79 M
|
$15.07 M
|
Other Expenses |
$1.83 M
|
$1.15 M
|
$1.47 M
|
$0.00
|
$1.44 M
|
$1.37 M
|
$2.14 M
|
$6.32 M
|
$9.83 M
|
$291,000.00
|
Operating Expenses |
$14.35 M
|
$9.44 M
|
$6.55 M
|
$5.69 M
|
$4.50 M
|
$5.06 M
|
$6.72 M
|
$11.44 M
|
$30.62 M
|
$15.37 M
|
Cost And Expenses |
$14.35 M
|
$9.44 M
|
$6.55 M
|
$5.69 M
|
$4.50 M
|
$5.06 M
|
$6.72 M
|
$11.44 M
|
$30.62 M
|
$15.37 M
|
Interest Income |
$687,000.00
|
$252,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$7.76 M
|
-$2.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
-$188,000.00
|
$2.27 M
|
-$5.79 M
|
$1.50 M
|
$1.44 M
|
$1.38 M
|
$2.14 M
|
$6.32 M
|
$9.83 M
|
$291,000.00
|
EBITDA |
-$14.35 M |
-$7.17 M |
-$12.34 M |
-$4.18 M |
$3.17 M |
-$1.93 M |
-$4.34 M |
-$45.15 M |
-$20.70 M |
-$17.67 M |
EBITDA Ratio |
0
|
0
|
0
|
-464.78
|
113.21
|
-1.56
|
-4.95
|
-1368.09
|
-2070.1
|
-654.59
|
Operating Income Ratio |
0
|
0
|
0
|
-631.67
|
-245.5
|
-3.09
|
-9.75
|
-1576.06
|
-3061.1
|
-568.41
|
Total Other Income/Expenses Net |
-$7.76 M
|
$2.27 M
|
-$5.79 M
|
$1.50 M
|
$8.60 M
|
$516,000.00
|
$2.08 M
|
$545,000.00
|
$79,000.00
|
-$2.62 M
|
Income Before Tax |
-$22.11 M
|
-$7.17 M
|
-$12.34 M
|
-$4.18 M
|
$1.73 M
|
-$3.31 M
|
-$6.48 M
|
-$51.47 M
|
-$30.53 M
|
-$17.97 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
-464.78
|
61.68
|
-2.67
|
-7.38
|
-1559.55
|
-3053.2
|
-665.37
|
Income Tax Expense |
$7.76 M
|
-$2.27 M
|
$0.00
|
$0.00
|
$8.60 M
|
$516,000.00
|
$2.08 M
|
$545,000.00
|
$79,000.00
|
-$2.62 M
|
Net Income |
-$29.87 M
|
-$4.90 M
|
-$12.34 M
|
-$4.18 M
|
$1.73 M
|
-$3.31 M
|
-$6.48 M
|
-$51.47 M
|
-$30.53 M
|
-$17.97 M
|
Net Income Ratio |
0
|
0
|
0
|
-464.78
|
61.68
|
-2.67
|
-7.38
|
-1559.55
|
-3053.2
|
-665.37
|
EPS |
-5.6 |
-2.97 |
-7.47 |
-28.31 |
15.48 |
-43.13 |
-126.45 |
-2195.79 |
-2123.52 |
-18733.06 |
EPS Diluted |
-5.6 |
-2.97 |
-7.47 |
-28.31 |
15.48 |
-43.13 |
-121.9 |
-2195.79 |
-2123.52 |
-18733.06 |
Weighted Average Shares Out |
$5.33 M
|
$1.65 M
|
$1.65 M
|
$147,739.00
|
$111,572.00
|
$76,658.00
|
$51,212.00
|
$23,438.00
|
$14,378.00
|
$959.00
|
Weighted Average Shares Out Diluted |
$5.33 M
|
$1.65 M
|
$1.65 M
|
$147,739.00
|
$111,572.00
|
$76,658.00
|
$53,126.00
|
$23,438.00
|
$14,378.00
|
$959.00
|
Link |
|
|
|
|
|
|
|
|
|
|